Alzheon
Overview[edit | edit source]
Alzheon is a biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders. The company is known for its work on small molecule therapies that target the underlying mechanisms of these diseases.
History[edit | edit source]
Alzheon was founded with the mission to address the unmet needs in the treatment of Alzheimer's disease. The company has been at the forefront of research into amyloid-targeting therapies, which aim to modify the course of the disease by reducing the accumulation of amyloid plaques in the brain.
Research and Development[edit | edit source]
Alzheon is actively involved in the development of ALZ-801, an oral small molecule that inhibits the formation of amyloid oligomers, which are believed to be toxic to neurons. This approach is based on the hypothesis that preventing the aggregation of amyloid-beta can slow or halt the progression of Alzheimer's disease.
ALZ-801[edit | edit source]
ALZ-801 is designed to be a prodrug of tramiprosate, which has shown potential in previous clinical trials. The drug is currently undergoing clinical trials to assess its efficacy and safety in patients with Alzheimer's disease, particularly those with a genetic predisposition to the condition.
Mechanism of Action[edit | edit source]
The mechanism of action of ALZ-801 involves the stabilization of amyloid-beta monomers, preventing their aggregation into toxic oligomers and fibrils. This is thought to protect neurons from the toxic effects of amyloid-beta, potentially slowing the progression of Alzheimer's disease.
Clinical Trials[edit | edit source]
Alzheon is conducting several clinical trials to evaluate the effectiveness of ALZ-801. These trials are designed to assess the drug's impact on cognitive function, biomarkers of Alzheimer's disease, and overall safety in patients.
Future Directions[edit | edit source]
Alzheon continues to explore additional therapeutic targets and strategies for treating Alzheimer's disease and other neurodegenerative disorders. The company is committed to advancing its pipeline of drug candidates and collaborating with the scientific community to bring new treatments to patients.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
